Table 1.
Groups of immunized animals | Day 0 | Days 21, 42 |
---|---|---|
1 A. 1 x HIVIS-DNA; 1x MVA | DNA id/EP | 1 x MVA im |
Content | Env A, B, C/Rev | Env E |
Content | Gag p37A B, RT B | Gag Pol A |
1 B. 1 x HIVIS-DNA; 2 x MVA | DNA id/EP | 2 x MVA im |
Content | Env A, B, C/Rev | Env E |
Content | Gag p37A B, RT B | Gag Pol A |
2 A. 1 x HIVIS-DNAopt; 1 x MVA | DNAopt id/EP | 2 x MVA im |
Content | Env A, B, C | Env E |
Content | Gag p37A B, RTPR B | Gag Pol A |
2 B. 1 x HIVIS-DNAopt; 2 x MVA | DNAopt id/EP | 2 x MVA im |
Content | Env A, B, C | Env E |
Gag p37A B, RTPR B | Gag Pol A | |
3 A. 1 x MVA | MVA im | |
Content | Env E | |
Content | Gag A, Pol A | |
3 B. 2 x MVA | MVA im | 1 x MVA im |
Content | Env E | Env E |
Content | Gag A, Pol A | Gag A, Pol A |
4. Naive controls | none | none |
Five Balb/c mice were immunized per group. HIV-DNA doses: 200 μg DNA Gag and RT/PR, 200 μg Env A-C, Rev/mouse/immunization; id Bioject and id EP. 107 pfu of MVA-CMDR/mouse was divided equally between the right and left hind legs, 50 μl/side. Mice were sacrificed at day 30 (groups 1A, 2A, 3 A), or days 63-70 (groups 1B, 2B, 3B).